Therapeutic Potential of Kappa-Opioids Against Cocaine - 1

NCT00000323 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2017-01-12

No results posted yet for this study

Summary

The purpose of this study is to characterize the effects of enadoline compared to hydromorphone and butorphanol.

Conditions

  • Cocaine-Related Disorders

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    lead NIH

Principal Investigators

  • Sharon Walsh, Ph.D. · Johns Hopkins University

Eligibility

Min Age
21 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1996-07-31
Completion
1998-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00000323 on ClinicalTrials.gov